**TABLE 1** C**linical and molecular features of patients with infant ALL**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| No. | Age（m） | Sex | Cell Origin | WBC(\*109/L) | HGB（g/L） | PLT(\*109/L) | Karyotype | KMT2A-r | Mutation gene | Chemotherapy | HSCT | Relapse/time after diagnosis（m） | Follow-up（m） | Outcome |
| 1 | 6 | Male | B cell | 40.52 | 36 | 27 | — | — | — | Yes\* | No | — | 4 | exitus |
| 2 | 7 | Female | B cell | 442 | 43 | 20 | — | — | — | No | No | — | 1 | exitus |
| 3 | 6 | Male | — | 513.07 | 73 | 61 | — | — | — | No | No | — | 1 | exitus |
| 4 | 9 | Female | — | 121 | 79 | 110 | — | — | — | No | No | — | — | — |
| 5 | 2 | Female | B cell | 46.4 | 93 | 50 | 46,XX,t(11;13)(q23;q22) | KMT2A/AFF1 | — | Yes\* | No | — | 4 | exitus |
| 6 | 2 | Male | B cell | 67.65 | 96 | 229 | — | KMT2A/AFF1 | — | No | No | — | 2 | exitus |
| 7 | 3 | Male | B cell | 39.7 | 54 | 24 | 46,XY | KMT2A/MLLT10 | None | Yes\* | No | — | 5 | exitus |
| 8 | 8 | Female | B cell | 21.1 | 24 | 36 | 46,XX | NO | TTN,NOTCH1 | Yes\* | No | — | 5 | exitus |
| 9 | 3 | Male | B cell | 74.92 | 104 | 144 | 46,XY,t(4,11)(q21;q23) | KMT2A/AFF1 | KRAS,GATA2,GATA1,EPPK1,PML,PDGFRA | Yes\* | No | — | 4 | exitus |
| 10 | 24d | Male | B cell | 211 | 120 | 24 | 46,XY,t(4,11)(q21;q23） | KMT2A/AFF1 | PTPN11,KRAS,TTN,NCOR1 | No | No | — | 2 | exitus |
| 11 | 28d | Female | B cell | 46.14 | 78 | 11 | 46,XX,t(9,11)(p22;q23） | — | — | No | No | — | 1 | exitus |
| 12 | 10 | Male | B cell | 33.46 | 97 | 56 | 46,XY,del(9)(p21)[13]/47,idem,+?21[3]/46,XY[4] | KMT2A/MLLT3 | NF1,KRAS,TTN | Yes | No | No | 18 | remission |
| 13 | 5 | Male | B cell | 15.29 | 66 | 10 | 47,XY,+X[2]/46,XY[1] | KMT2A-r | — | Yes | No | No | 38 | remission |
| 14 | 6 | Male | B cell | 470 | 66 | 72 | 46,XY | KMT2A/AFF1 | None | Yes | Yes | No | 6 | exitus |
| 15 | 5 | Male | B cell | 6.46 | 60 | 66 | No cell division | NO | — | Yes | No | No | 33 | remission |
| 16 | 11 | Male | B cell | 18.04 | 77 | 235 | No cell division | NO | None | Yes | No | No | 9 | remission |
| 17 | 10 | Female | B cell | 41.69 | 72 | 111 | 46,XX,del(14)(q13),add(20)(q11,2)[2]/46,XX[18] | KMT2A-r | None | Yes | No | Yes/10 | 10 | exitus |
| 18 | 8 | Female | B cell | 313.56 | 50 | 22 | — | KMT2A/MLLT10 | — | Yes | Yes | Yes/6 | 9 | exitus |
| 19 | 4 | Female | B cell | 33.8 | 40 | 237 | 46,XX | NO | None | Yes | Yes | No | 30 | remission |
| 20 | 11 | Male | B cell | 26.4 | 77 | 69 | 46,XX | KMT2A/MLLT10 | KDM2B | Yes | No | No | 9 | remission |
| 21 | 4 | Female | B cell | 148.12 | 73 | 34 | 46,XX,t(4,11)(q21;q23) | KMT2A/AFF1 | TTN,NRAS,PTPN11,KRAS,TP53 | Yes | No | Yes/4 | 5 | exitus |
| 22 | 3 | Female | B cell | 61.78 | 110 | 505 | 46,XX,-4,-14,add(19)(q13),+2mar[5]/46,XX,[15] | NO | TET2,ASXL1 | Yes | No | Yes/12 | 63 | remission |
| 23 | 5 | Female | B cell | 17.16 | 81 | 21 | 46,XX,t(4,11)(q21;q23) | KMT2A/AFF1 | NRAS | Yes | No | — | 6 | exitus |

No.: number; m: months; d: day; KMT2A-r: KMT2A rearrangement; HSCT: Hematopoietic Stem Cell Transplantation; —: lack of information; Yes\*: patients who received short-term chemotherapy but unfinished VDLD regimen